We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





HEMCO Corporation’s MicroFlow I Ductless Workstation Ensures Safety Comes First

By LabMedica International staff writers
Posted on 29 May 2020
Amidst the current pandemic, laboratory biosafety related to the coronavirus has assumed significant importance for laboratories and stakeholders involved in COVID-19 laboratory work.

HEMCO Corporation (Independence, MO, USA), a leading manufacturer of innovative laboratory equipment since 1958, is uniquely qualified to provide laboratory planning solutions due to its many years of experience. More...
The company manufactures and distributes laboratory fume hoods, casework, vented enclosures, modular clean labs, and laboratory safety equipment, as well as laboratory planning solutions to sciences and research and development technology industries.

The MICROFLOW I from HEMCO is a ductless, carbon filtered, rust resistant workstation equipped with activated carbon filtration, designed to collect small amounts of non-hazardous fumes and odors. The workstation is completely self contained and can be easily moved from station to station. It comes with an integral recessed work surface to contain spills and a clear hood surround with safety viewing sash for users. Sash can be conformed for use with a microscope, and variable speed fan control provides the option of high and medium speeds, orlow flow for sensitive operations. The MICROFLOW I operates on 115v AC, or 230v international, and conforms to UL, CSA, and CE requirements.

Related Links:
HEMCO Corporation


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.